Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous lidocaine versus dupilumab for moderate-to-severe atopic dermatitis
ChiCTR2300075565Phase 4Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in atopic dermatitis (AD) comparing Lidocaine group with Dupilumab group (2 arms). Primary endpoint: Eczema Area and Severity Index 50 response ratio. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
lidocainedupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2300075565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075565.